Leti and ARaymondlife Launch Project
News Apr 09, 2016
Leti and ARaymondlife have announced a joint initiative to accelerate the development and manufacturing of innovative medical devices, especially in the field of microfluidic cartridge analysis. The initiative, based on experiences from ongoing projects, will focus on cartridges that enclose portable bio-med systems that enable sample analysis where the patient is dramatically reducing both the time to see the results and the cost of an analysis.
More broadly, Leti and ARaymondlife will collaborate on future projects that capitalize on their complementary strengths. Leti has joined the network of selected partners initiated by ARaymondlife according to their know-how and capabilities to guide its product-development projects, and ARaymondlife is a preferred partner for the development platform of medical devices that Leti has recently established.
“This partnership combines our competencies in ways that will significantly speed the development and time-to-market of analytical tools and systems for Leti’s partners and ARaymondlife customers,” said Leti CEO Marie Semeria. “It also capitalizes on the technological diversity of the local ecosystem and underscores the Grenoble region’s excellence in medical technology.”
By combining their complementary strengths, the partners expect to support the development
of turnkey solutions for companies that want to introduce new products in the medical technology industry, but require additional analytical resources, technical competencies or manufacturing tools.
“The strict standards and high costs for developing medical devices require that prototypes used for clinical testing not only meet quality regulations, but that also are almost identical to the final product,” said Philippe Daurenjou, ARaymondlife Commercial Director. “This partnership with Leti uses our complementary strengths to meet those requirements effectively and cost efficiently, and make our customers more competitive.”
The two partners anticipate working together on projects that will combine Leti’s expertise in developing analytical protocols with Araymondlife’s manufacturing capacity. On those projects, ARaymondlife would be involved very early in the development cycle to check the viability of the proposed solution in the manufacturing processes. The team will make modifications to improve the reliability of the product and reduce production costs, as needed.
In addition to its med-tech uses, Leti’s technology also is well-suited for rapid and cost-effective onsite analysis in environmental, agricultural and veterinary applications.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019